Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Anti-Bacterial Agents; Vancomycin

Criteria

Inclusion Criteria:

• All patients admitted to or transferred to the MICU.

• Patients 18 years of age or older.

• Provide written informed consent.

Exclusion Criteria:

• Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae.

• Patients who have hypersensitivity to penicillin.

• Any underlying conditions or diseases that will be ultimately fatal within 48 hours.

• Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.